Abstract
The insulin-like growth factor pathway plays a major role in cancer cell proliferation, survival and resistance to anti-cancer therapies in many human malignancies, including breast cancer. As a key signaling component of IGF system, the IGF-1 receptor is the target of several investigational agents in clinical and pre-clinical development. This review will focus on the rationale for targeting the IGF-1 receptor and other components of the IGF-1 system. In addition, we will examine the role of IGF-1 signaling in resistance to clinically important breast cancer therapies, including cytotoxic chemotherapy, hormonal therapy and erbB targeted agents. We will also review the completed and ongoing clinical investigations with IGF-1 receptors inhibitors to date and the utility of these early data in designing future breast cancer studies with IGF-1 signaling inhibition strategies.
Original language | English (US) |
---|---|
Pages (from-to) | 471-483 |
Number of pages | 13 |
Journal | Journal of mammary gland biology and neoplasia |
Volume | 13 |
Issue number | 4 |
DOIs | |
State | Published - 2008 |
Keywords
- Clinical trials - Phase I
- Clinical trials - Phase II
- Drug resistance
- IGF-1R inhibition
- IGFType I
- Monoclonal antibody
- Receptor
- Receptor crosstalk
- Tyrosine kinase inhibitors
ASJC Scopus subject areas
- Oncology
- Cancer Research